CAN1012 Combined With PD-1 in Patients With Solid Tumors - Trial NCT06410703
Access comprehensive clinical trial information for NCT06410703 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Canwell Biotech Limited and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 71 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Canwell Biotech Limited
Timeline & Enrollment
Phase 1/2
May 30, 2024
May 30, 2026
Primary Outcome
Safety and tolerability
Summary
This is a Phase Ia/IIb, open-label, first-in-human, multicenter, single-arm, dose escalation
 study of intratumoral CAN1012 combined with PD-1 in patients with Unresectable or Metastatic
 Advanced Solid Tumors who have exhausted options for standard of care therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06410703
Non-Device Trial